Habig Scott Michael
Known title: Chief Commercial OfficerCIK: 0001938159
Habig Scott Michael's purchase track record
Habig Scott Michael has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/9/2022 | AUPH | $25K | +68.6% | +123.5% | +10.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AUPH | ▼ Sell | Open Market | 18,249 | $97K | 8/6/2024 | View on chart |
| AUPH | ▼ Sell | Open Market | 17,777 | $100K | 3/6/2024 | View on chart |
| AUPH | ▲ Buy | Grant | 195,512 | $0 | 2/20/2024 | View on chart |
| AUPH | ▼ Sell | Open Market | 15,867 | $87K | 2/20/2024 | View on chart |
| AUPH | ▲ Buy | Grant | 170,188 | — | 3/2/2023 | View on chart |
| AUPH | ▲ Buy | Open Market | 5,000 | $25K | 11/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity
Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.